Unique off-the-shelf therapeutic DC-cancer vaccine in clinical trials
|
|
- Kory Jones
- 5 years ago
- Views:
Transcription
1 Unique off-the-shelf therapeutic DC-cancer vaccine in clinical trials BUSINESS DESCRIPTION Immunicum AB (publ) is a biopharmaceutical company that develops unique therapeutic cancer vaccines (INTUVAC is the most advanced and based on the COMBIG-platform). Immunicum seeks to enter partnerships with, and to out-license its products to, larger pharmaceutical companies interested in immunotherapy. The company was founded in 2002 as a spin-off from Sahlgrenska University Hospital in Gothenburg, Sweden. THE NEW SHARE ISSUE This is Immunicum ABʼs 4th tranche of new shares to be issued, bringing in 21.5 MSEK in new financing. With this new financing, Immunicum s goals throughout 2014 are to: Complete the ongoing clinical phase I/II trial in renal cell carcinoma in Sweden and an upcoming clinical phase I/II trial in a new indication. Receive orphan drug designation for INTUVAC in a new indication. 1) Allogeneic DCs are injected TECHNOLOGY DESCRIPTION 2) NK-cells are recruited to the Immunicum has developed therapeutic cancer vaccines based on the unique approach of using dendritic cells (DCs) from healthy donors, in contrast to all other DCcancer vaccine competitors that are using DCs from each patient to be treated. The technologies are based on over intratumorally. tumor where they induce an NK-cell mediated tumor cell death, thus releasing tumor antigens ready for 30 years of research within the area of transplantation uptake by antigen-presenting-cells such immunology. The US-market approval for Provenge as DCs. (Dendreon) in 2010 and recent advances in the understanding of DC-based vaccine approaches appear 3) Autologous DCs are recruited to the tumor to have stimulated increased interest in this class of where they engulf tumor antigens and migrate vaccine. In fact, the Nobel Prize in Medicine 2011 was to the draining lymph nodes. awarded the discoverer of the DC, the most efficient antigen-presenting cell known today. 4) DCs present tumor antigens to naïve T-cells who subsequently become tumor specific cytotoxic T-lymphocytes (CTLs). Figure 1: Description of INTUVACʼs meachnism of action.
2 There are four major advantages of INTUVAC 1. The vaccine targets any cancer in patients who have a solid tumor eligible for intratumoral injection. 2. INTUVAC is patient independent and possible to mass produce. 3. The concept utilizes the patients own tumor antigens, thus guaranteeing an optimal battery of tumor antigens to be used for each individual patient in the activation of a tumor-specific immune response. 4. Immunicum is not dependent on third party antigen inlicensing. tumor and two patientsʼ extracted primary tumors. The tumors in picture 2 have been stained for CTLs and show a substantial increase of infiltrating CTLs in both patientsʼ extracted primary tumors in comparison to untreated tumors after INTUVAC-RCC vaccination. Strengths and opportunities Promising clinical data on CTL infiltration response. Orphan drug designations for both RCC and melanoma. Experienced team. Cancer vaccine immunotherapy area with recent clinical and commercial success stories. Immunicum s project portfolio Immunicum s project portfolio consists of four different entities (see figure 2 on the next page). This document will however mostly focus on projects based on the prioritized vaccine INTUVAC. INTUVAC-RCC INTUVAC is currently used in a clinical phase I/II trial in renal cell carcinoma (RCC) in Sweden (see picture 1). The trial will be conducted on 12 patients and is expected to be completed by Q Thus far, patients that have been treated with INTUVAC show promising immunological response, no adverse effects, and clear signs of health improvements. Picture 1: The first INTUVAC-RCC vaccination. INTUVAC-clinical data gathered thus far are promising The patientʼs primary tumor, along with the entire kindey, is extracted, which gives Immunicum an interesting opportunity to analyze the immunological response one month after first vaccination. Picture 2 a-d below shows a comparison of the infiltration of CD8+ T-cells/CTLs (the cells that have the ability to fight cancer) in an untreated Untreated tumor! a) Treated tumor, first patient! b) Treated tumor, second patient! c) Treated kidney/healthy tissue, d) second patient! Picture 2 a-d: A comparison of the infiltrating CD8+ T-cells/CTLs (black stains) in treated and untreated tumors. Untreated tumor (a) shows an average of 15 CTLs per investigated area, to compare with an average of 42 CTLs for the first patient (b) and 300 CTLs for the second patient (c). Rightmost picture (d) shows lack of infiltrating CTLs in the healthy tissue of the treated kidney which indicates that the CTLs are tumor specific.
3 Figure 2: Immunicumʼs project pipeline. MARKET ANALYSIS In 2009, the global cancer vaccine market was estimated to be worth $1,8 billion. By year 2020, this number is expected to have risen to $8 billion, thanks to the introduction of new therapeutic cancer vaccines and an increasing number of cancer patients. The number of people living with cancer is expected to have increased by 50 % in year Thus, the total market for therapeutic cancer vaccines has multi-billion dollar potential. Approximately new cases of RCC are diagnosed worldwide each year, representing about two percent of all cancers. GlobalData estimates that the global RCC market was valued at $1.3 billion in 2009 and is forecast to grow and reach $3.8 billion by Competition The arrival of Sutent and other targeted drugs represents a major step forward compared to the previous standard treatment of RCC. Most of the new treatments target tyrosine kinase pathways and block angionesis, the formation of new blood vessels which help the tumour grow. Sutent earned $1.066 billion in worldwide sales in 2010 according to Pfizerʼs annual report. Even though Sutent and other targeted drugs on the market have been shown to prolong overall survival of metastatic RCC-patients, there is room for improvement, as these drugs are associated with adverse effects, and numerous pharma companies are looking to produce a drug which will represent this next step forward. Immunicum has also identified four (4) companies that are currently developing therapeutic RCC-vaccines (phase I/II-III), however all these vaccines have important drawbacks in comparison to INTUVAC. About 26% of identified therapeutic cancer vaccines in clinical development are antigen-based vaccines and thus ideal to combine with Immunicum s core-concept. All companies in need of effective adjuvants,in addition to all companies that are focused on using patients own (autologous) white blood cells, are considered potential partners. Increased interest in therapeutic cancer vaccines Big Pharma seek partnerships with small Biotechs as part of their strategic plan for acquisition of novel technologies and new drug candidates. Several Big Pharma, such as Pfizer and Eli Lilly, have recently also shifted strategic focus to the oncology market and more emphasis has been placed on developing cancer vaccines. In addition, there has been a renewed interest in cancer immunotherapy due to the first approval of a therapeutic cancer vaccine (Provenge) in the US in An increased interest in cancer vaccines can be exemplified by the billion dollar deal Amgen struck with BioVex in January 2011 to gain access to their late stage therapeutic cancer vaccine OncoVex.
4 ORGANIZATION Immunicum s team brings front edge competence in cancer immunology together with extensive experience from commercial drug development. Immunicum s Chairman of the Board is Agneta Edberg, current CEO of Mylan Nordic. Agneta Edberg has held leading positions within Pfizer and Pharmacia in addition to having been COO for the venture capital firm LinkMed. Bengt Furberg is an expert in clinical trials and has written several books and scientific articles within the field. He spent 10 years as Medical Director at GlaxoWellcome in Sweden and was also part of the company's management team in addition to being member of the corporate group's Medical Board and Safety Board. Per-Olof Gunnesson has over 40 years of experience from the pharmaceutical industry. He has held several management positions at the Astra Group where he also acted as VP of Finance and Licensing. Two of Immunicum s founders, Alex Karlsson-Parra (acting Chief Scientific Officer) and Bengt Andersson, are also members of the Board. They bring over 25 years of experience each from transplantation and infection immunology, in the order given. Jamal El- Mosleh is acting CEO of Immunicum since 2007 and is a graduate from Chalmers University of Technology (Industrial Engineering and Management) and Göteborg International Bioscience Business School (Innovation and Entrepreneurship). He previously worked as a management consultant and as a manager for a biotech startup. Scientific Advisory Board Immunicum has also established a Scientific Advisory Board (SAB), headed by Bengt Furberg, with a very diverse set of important competencies. Rolf Kiessling, MD, PhD, is professor in Experimental Oncology at Karolinska Institutet since 1995 and is a worldrenowned clinical immunologist, among other things known for having discovered and named the Natural Killer (NK)- cell. His group is carrying out investigator initiated clinical trials on cancer patients and also performs basic research in preclinical animal models. Roger Henriksson, one of Sweden s most prominent clinical oncologists is a professor in Experimental Oncology and Chief Physician, Medical Oncology and Radiotherapy since He currently works as Chief of the Regional Cancer Center Stockholm-Gotland. Curt Furberg is an internationally recognized cardiovascular epidemiologist with expertise in clinical trials and public health. He has served on the FDA Advisory Committee on Drug Safety and Risk Management and testified before Congress. Dr. Furberg s honors and awards include the National Institutes of Health Director s Award and the Established Investigator in Clinical Science Award. Finally Dan Magnusson holds a M.Sc. in Pharmacy and Economy and brings broad experience from pharmaceutical industry production and from acting as Qualified Person. Previous experiences include working as International Marketing Manager for Astra/Hässle for the international launch of Losec. FINANCING Total funding to date amounts to approximately 24 MSEK. This funding includes a major grant of 3.5 MSEK in 2010 from The Swedish Governmental Agency for Innovations Systems (VINNOVA s) program Innovations for future health. Among a total of 250 applicants, Immunicum was one of 13 organizations which received funding, after having been reviewed by 17 experts in different areas, based on the following motivation: The application describes an interesting and important project with possibilities of hindering growth and development of existing tumors, and a vision of hindering growth of new tumors. The concept is based on well-founded research. There is good potential that the treatment will be used as a cancer therapy, as well as for other indications. The application has a good clinical relevance, patent strategy, and commercialization plan. OWNERSHIP STRUCTURE As of today, Immunicum has a total of 16 shareholders in addition to seven owners of options with the right to buy shares in the company. The three largest shareholders are: Loggen Invest AB (27%), Holger Blomstrand Byggnads AB (21%), and Chalmers Innovation (15%). The CEO currently owns 4,4% of Immunicum.
5 INTELLECTUAL PROPERTY Immunicum s patent portfolio consists of six patent families protected by one approved Swedish patent, one approved European patent, and six pending patent applications. Former Head of the Patent and Trademark Department at Astra AB, Gerhard Miksche, made the following statement after having reviewed Immunicumʼs patent portfolio: The patent portfolio of Immunicum is varied and well adapted to the business idea. While about half of the patent term of the basic patent family A has passed, later filed patent applications protect important improvements of the basic concept, and thus secure a factual monopoly extending far beyond the term of the basic patents. The main inventor s good understanding of the patent system is a nonnegligible asset of the company. We recently met with representatives of Immunicum who presented the COMBIG concept of allo-dc vaccination. The concept that allo-vaccination with DCs triggers a cascade of immune responses including innate (NK cell activation) and subsequent adaptive, antigen specific responses is interesting and is deserving of further development. We are fully supportive of this work and believe that this allo-dc model may well result in the initiation of anti-tumoural responses where in vitro manipulated autologous DCs have limitations both in terms of GMP manufacture and in their capacity to generate consistent clinical responses. Our own clinical experience suggests that such an approach would be of benefit in melanoma and a range of other solid tumours. Professor Angus Dalgleish, principal of CVI. Dendritic cell, loaded with tumor antigens
For personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationImmunicum AB Innovation in Immuno-Oncology
Immunicum AB Innovation in Immuno-Oncology Småbolagsdagen Stockholm, 12 June 2017 Carlos de Sousa, CEO Safe Harbor This presentation contains forward-looking statements that involve substantial risks and
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationANALYSIS BY ASSIGNMENT May 17, 2018 IMMUNICUM ANALYSGUIDEN
Contents Targeting new trial start... 2 Share Temperature... 3 Management... 3 Owners... 3 Financial position... 3 Potential... 3 Risk... 3 Investment case... 4 Funding likely to last into H1 2019... 5
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationAPPENDIX "C" COMPANY DEVELOPMENT PIPELINE
Horse Horse APPENDIX "C" COMPANY DEVELOPMENT PIPELINE Animal Cancer Vaccines AUTOLOGOUS Preclinical Approval ALLOGENEIC Preclinical Approval DIRECT INJECTION Preclinical Approval Horse Q4 2016 Human Cancer
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationNEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationQUARTERLY REPORT 1. September 2016 November Diamyd Medical AB (publ), Fiscal year 2016/2017
QUARTERLY REPORT 1 September November Diamyd Medical AB (publ), Fiscal year /2017 Reporting period, September 1, November 30, Net result amounted to MSEK -4.3 (-4.3) Net result per share amounted to SEK
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationNew Generation of T-cell Therapeutics
New Generation of T-cell Therapeutics Corporate Overview January 2017 NASDAQ: TPIV 1 Safe Harbor Statement Certain statements contained herein are forward-looking statements within the meaning of the safe
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationProprietary Pipeline
Revenue Generating Commercial portfolio with highquality, differentiated products in the Canadian market Proprietary Pipeline Reformulation development pipeline for drugs with a need for improved compliance
More informationAt the forefront of Immuno-Oncology With T-Cell Therapeutics OTCMKTS: TPIV.
At the forefront of Immuno-Oncology With T-Cell Therapeutics OTCMKTS: www.tapimmune.com CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information(908) (908)
Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationCase 2:09-cv FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5. Exhibit B
Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 1 of 5 Exhibit B Case 2:09-cv-04329-FSH-PS Document 1-3 Filed 08/24/2009 Page 2 of 5 TO OUR FELLOW SHAREHOLDERS: In 2001 we made significant
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationIntroducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)
Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) CED Life Science Conference February 27, 2018 Almost 40% of us will be diagnosed with cancer at some point in our lives
More informationYour contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
Your contact Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 News Release Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 May
More informationMerriman Investment Summit 2009
Merriman Investment Summit 2009 10 November 2009 Robert Klupacs, CEO & Managing Director Circadian Technologies (ASX.CIR) Disclaimer Investment in Circadian Technologies Limited ( Circadian ) is subject
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationYour Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Lisa O Neill +44 1737 331536 Investor
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationYEAR END REPORT. September 2013 August Diamyd Medical AB (publ), Fiscal year 2013/2014
YEAR END REPORT September 2013 August 2014 Diamyd Medical AB (publ), Fiscal year 2013/2014 Reporting period, June 1, 2014 August 31, 2014 Net sales amounted to MSEK 0.2 (0,1) Loss before tax amounted to
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationOur research for you. German Equity Forum November 2011
Our research for you. German Equity Forum 21-23 November 2011 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationWelcome to Galenicum! APRIL, 2013
Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who
More informationResearch For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer
Research For the Future Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer 1 2 ATTACKING CANCER FROM EVERY ANGLE 3 CANCER PREVENTION STUDIES (CPS) Intramural Research Smoking Obesity
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationBioDiem to present at Hong Kong biotech investment forum
ASX Announcement BIODIEM LTD ABN 20 096 845 993 Suite 3, Level 11, 470 Collins Street, Melbourne, Victoria, 3000 Australia Phone: +613 9613 4100 Web: www.biodiem.com BioDiem to present at Hong Kong biotech
More informationModiQuant Technology Innovative assessment of modified proteins. Massimo Papale CEO & Co-Founder
ModiQuant Technology Innovative assessment of modified proteins Massimo Papale CEO & Co-Founder Our Milestones January 2016 Patent application for R/pR test June 2016 Keep Calm & Startup Foggia Prize October
More informationCatalyzing the Next Generation of Cancer Technologies
Catalyzing the Next Generation of Cancer Technologies Presentation to the IOM Workshop on the Cures Acceleration Network June 4, 2012 Michael Weingarten Director, NCI SBIR Development Center Today s Presentation
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationManaging out-licensing collaborations: a big pharma perspective
Managing out-licensing collaborations: a big pharma perspective Arne Wörn, PhD, Head Alliance Management IID European PLG Conference, Copenhagen, Sept. 5-6 These materials contain certain forward-looking
More informationDeborah Rathjen CEO & Managing Director 2014 Annual General Meeting
Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director 2014 Annual General Meeting Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationGalvus US NDA Approvable - Overview
Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient
More information